ELISA/assay

Human Adenosine Deaminase ELISA Kit

MBS733123

48-Strip-Wells

440 USD

ELISA Kit

Human Adenosine Deaminase ELISA Kit

[Adenosine Deaminase]

[adenosine deaminase; Adenosine deaminase; adenosine deaminase; adenosine aminohydrolase; adenosine deaminase; Adenosine aminohydrolase]

[ADA]

[ADA; ADA; ADA1]

ADA_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of ADA. No significant cross-reactivity or interference between ADA and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between ADA and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Typical Testing Data/Standard Curve (for reference only)

Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate. Assay Type: Quantitative Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This ADA ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human ADA. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: ADA ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-ADA antibody and an ADA-HRP conjugate. The assay sample and buffer are incubated together with ADA-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the ADA concentration since ADA from samples and ADA-HRP conjugate compete for the anti-ADA antibody binding site. Since the number of sites is limited, as more sites are occupied by ADA from the sample, fewer sites are left to bind ADA-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The ADA concentration in each sample is interpolated from this standard curve.

47078295

NP_000013.2

NM_000022.2

40,764 Da

C-MYB Transcription Factor Network Pathway (138073); Metabolic Pathways (132956); Metabolism Pathway (477135); Metabolism Of Nucleotides Pathway (106263); Primary Immunodeficiency Pathway (83125); Primary Immunodeficiency Pathway (537); Purine Metabolism Pathway (82944); Purine Metabolism Pathway (106265); Purine Metabolism Pathway (307); Purine Salvage Pathway (106273)

This gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine. Various mutations have been described for this gene and have been linked to human diseases. Deficiency in this enzyme causes a form of severe combined immunodeficiency disease (SCID), in which there is dysfunction of both B and T lymphocytes with impaired cellular immunity and decreased production of immunoglobulins, whereas elevated levels of this enzyme have been associated with congenital hemolytic anemia. [provided by RefSeq, Jul 2008]

ADA: a enzyme that converts adenosine + H2O into inosine + NH3. Found in all tissues, occurs in large amounts in T-lymphocytes and, at the time of weaning, in gastrointestinal tissues. Genetic ADA deficiencies are a cause of autosomal recessive severe combined immuno-deficiency (SCID). Hereditary hemolytic anemia is caused by expression levels in erythrocytes 50-70 times greater than the norm. Protein type: Nucleotide Metabolism - purine; Hydrolase; EC 3.5.4.4. Chromosomal Location of Human Ortholog: 20q13.12. Cellular Component: dendrite cytoplasm; extracellular space; cell surface; membrane; cell soma; lysosome; cytoplasm; plasma membrane; cytosol; cell junction; external side of plasma membrane. Molecular Function: adenosine deaminase activity; protein binding; zinc ion binding; purine nucleoside binding. Biological Process: negative regulation of circadian sleep/wake cycle, non-REM sleep; T cell activation; adenosine catabolic process; deoxyadenosine catabolic process; response to morphine; positive regulation of calcium-mediated signaling; purine salvage; histamine secretion; positive regulation of T cell differentiation in the thymus; purine ribonucleoside monophosphate biosynthetic process; response to vitamin E; regulation of cell-cell adhesion mediated by integrin; positive regulation of T cell receptor signaling pathway; negative regulation of mature B cell apoptosis; positive regulation of germinal center formation; positive regulation of B cell proliferation; hypoxanthine salvage; negative regulation of adenosine receptor signaling pathway; positive regulation of smooth muscle contraction; embryonic gut development; aging; placenta development; response to drug; Peyer s patch development; dATP catabolic process; nucleobase, nucleoside and nucleotide metabolic process; positive regulation of heart rate; liver development; negative regulation of leukocyte migration; purine base metabolic process; trophectodermal cell differentiation; purine nucleotide salvage; xanthine biosynthetic process; response to hydrogen peroxide; negative regulation of inflammatory response; response to hypoxia; inosine biosynthetic process; germinal center B cell differentiation; alveolus development; positive regulation of alpha-beta T cell differentiation. Disease: Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-negative, B Cell-negative, Nk Cell-negative, Due To Adenosine Deaminase Deficiency

48-Strip-Wells

440 USD

96-Strip-Wells

640

5x96-Strip-Wells

2895

10x96-Strip-Wells

5415